Clinical trial · Interventional
Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma
Treatment of Intracranial Germinoma With Chemotherapy Prior to Reduced Dose and Volume of Radiotherapy
NCT02782754CI-TRIAL-00022378unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the outcome of intracranial germinoma treated with chemotherapy plus reduced radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intracranial Germinoma | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bleomycin | Drug | Bleomycin | ALIAS |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Reduced dose of radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intracranial germinoma
- description
- 1. Four cycles of chemotherapy with carboplatin, etoposide, (+ bleomycin) and cyclophosphamide, etoposide, (+ bleomycin) regimen 2. Reduced dose of radiotherapy * Without seeding: 18 Gy to ventricle + 12.6 Gy to primary site * With seeding: craniospinal irradiation 18 Gy + 12.6 Gy to primary site
- interventionNames
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Cyclophosphamide
- Drug: Bleomycin
- Radiation: Reduced dose of radiotherapy
Primary outcomes (1)
- measure
- Rate of late sequelae
- timeFrame
- Up to 5 years
Secondary outcomes (1)
- measure
- Rate of event free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with pathologically proven intracranial germinoma Exclusion Criteria: * Elevated serum/cerebrospinal fluid alpha-feto protein * Patients with organ dysfunction as follows (creatinine elevation, ejection fraction, liver function test \> CTCAE grade 2)
References
Publications (1)
- DERIVEDLee JW, Lim DH, Sung KW, Cho HW, Ju HY, Yoo KH, Koo HH, Kim JH, Suh YL, Shin HJ. Induction Chemotherapy Reduces Radiation Therapy Dose and Volume in the Treatment of Intracranial Germinoma: Results of the SMC-G13 Trial. Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):649-656. doi: 10.1016/j.ijrobp.2020.05.051. Epub 2020 Jun 2. PMID 32502506